Pharmaceuticals

Edgewise Therapeutics

Servier to Acquire Edgewise Therapeutics Muscular Dystrophy Business for $2.65 Billion

Edgewise Therapeutics released FY2026 Q1 earnings on May 7 Pre-Market EST, actual EPS USD -0.4599 (forecast USD -0.4855)

Edgewise Therapeutics to Release FY2026 Q1 Earnings on May 7 Pre-Market EST, Forecast EPS USD -0.492

Edgewise Therapeutics released FY2025 Q4 earnings on February 26 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4735 (forecast USD -0.4376)

Edgewise Therapeutics released FY2025 annual earnings on February 26 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.6301 (forecast USD -1.5955)

Edgewise Therapeutics Advances Clinical Pipeline for Muscular Dystrophy and Cardiac Diseases

Edgewise Therapeutics Receives Consensus Analyst Rating

Analyst Maintains Hold Rating on Edgewise Therapeutics

Edgewise Therapeutics announces positive interim safety results for drug EDG-7500 trial

Evercore ISI Analyst Maintains Buy Rating on Edgewise Therapeutics

JP Morgan Raises Target Price, Driving Edgewise Therapeutics Stock Up

Piper Sandler Analyst Maintains Buy Rating for Edgewise Therapeutics

H.C. Wainwright Reiterates Buy Rating on Edgewise Therapeutics

Edgewise Therapeutics released FY2025 9 Months Earnings on November 6 Pre-Market EST, actual revenue USD 0, actual EPS USD -1.1584

Edgewise Therapeutics released FY2025 Q3 earnings on November 6, Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.39 (forecast USD -0.3932)

Edgewise Therapeutics to Release FY2025 Q3 Earnings on November 6, Pre-Market EST, Forecast EPS USD -0.3985

Analyst Gives Edgewise Therapeutics a Buy Rating

Edgewise Therapeutics, Inc. Lists on NASDAQ

JPMorgan 下调 Edgewise Therapeutics 目标股价

Edgewise Therapeutics released FY2025 Semi-Annual earnings on August 7 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7686 (forecast USD -0.84)

VS MEDIA

Big Tree Cloud

Tianci

Fold

Pop Culture

ChowChow Cloud

Green Circle Decarbonize Tech

Autozi Internet Tech Global

Hitek Global Inc.

EWTX

JBIO

PRAX

IDYA

Wedbush adjusted analyst ratings for four biotech firms: Praxis (PRAX) price target cut to $162 after POWER1 trial miss; IDEAYA (IDYA) and Edgewise (EWTX) retain Outperform ratings with targets of $58 and $52 respectively, following positive OptimUM-02 data and a $1.55B Servier deal; Jade Biosciences (JBIO) target raised to $45 on strong JADE101 Phase 1 data.

rttnews

Jade Biosciences

Praxis Precision Medicines

Ideaya Biosciences

Wedbush Analyst Ratings On PRAX, IDYA, EWTX, JADE

Edgewise Therapeutics (Nasdaq: EWTX) announced inducement grants of stock options for 74,000 shares to four new non-executive employees under its 2024 Inducement Equity Incentive Plan. The options, priced at $34.16 per share, vest over a four-year period starting one year after employment commencement. These grants were made pursuant to Nasdaq Listing Rule 5635(c)(4) as material inducements for the new hires.

prnewswire

16:01 ETEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Servier has agreed to acquire Edgewise Therapeutics' muscular dystrophy business for $2.65 billion, comprising a $1.55bn upfront payment and up to $1.1bn in milestones. The deal includes the asset sevasemten, currently in development for Becker and Duchenne muscular dystrophies. Approved by both boards, the transaction awaits regulatory clearance and is expected to close in Q3 2026, aligning with Servier's rare neurology strategy.

Pharmaceutical Technology

Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn

FLNC

TMHC

SPCE

BRK.B

BRK.A

While the Dow fell over 65 points, several stocks surged. Optimum Communications led gains with a 93.71% jump following a tender offer to buy back shares. Other notable gainers included Fluence Energy (+34.58%), Virgin Galactic (+28.80%), and Elmet Group (+25.0%) on strong earnings. Taylor Morrison rose 22.46% after Berkshire Hathaway agreed to acquire it for $6.8 billion. Edgewise Therapeutics gained 14.72% after selling its muscular dystrophy business for $2.65 billion.

- U.S. stocks declined, with the Dow dropping over 65 points, although several technology, energy, and aerospace stocks saw significant gains.  
- Optimum Communications Services Inc. led the rally, surging 93.71% to $1.27 following a tender offer to buy back up to 120 million shares at $2.50 each.  
- Other notable gainers included Fluence Energy (+34.58%), Virgin Galactic (+28.80%), and Taylor Morrison Home Corporation (+22.46%) after a $6.8 billion acquisition announcement.

benzinga_article

Fluence Energy

Taylor Morrison Home

Virgin Galactic

Berkshire Hathaway B

Berkshire Hathaway

Dow Jones Industrial Average

Optimum Communications

Elmet

NVIDIA

Replimune

AirJoule Tech

Asana

NVIDIA Corporation

AIRJOULE TECHNOLOGIES CORP C/WTS 15/03/2029(TO PUR COM)

Optimum Communications, Fluence Energy, Virgin Galactic And Other Big Stocks Moving Higher Today

Edgewise Therapeutics(EWTX.US)

Wedbush Analyst Ratings On PRAX, IDYA, EWTX, JADE

16:01 ETEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn

Optimum Communications, Fluence Energy, Virgin Galactic And Other Big Stocks Moving Higher Today